Biomarkers of Therapeutic Response in Melanoma and Renal Cell Carcinoma: Potential Inroads to Improved Immunotherapy
- 1 June 2009
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (16) , 2583-2585
- https://doi.org/10.1200/jco.2008.21.1540
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 TherapyJournal of Clinical Oncology, 2009
- Impact of IFNα2b upon pSTAT3 and the MEK/ERK MAPK Pathway in MelanomaCancer Immunology, Immunotherapy, 2008
- Down-Regulation of the Interferon Signaling Pathway in T Lymphocytes from Patients with Metastatic MelanomaPLoS Medicine, 2007
- Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon-α2bClinical Cancer Research, 2007
- Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2bClinical Cancer Research, 2007
- Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune ResponsesJournal of Clinical Oncology, 2006
- Prognostic Significance of Autoimmunity during Treatment of Melanoma with InterferonNew England Journal of Medicine, 2006
- Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancyBritish Journal of Cancer, 2003
- Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or MelanomaThe Journal of Experimental Medicine, 2002
- Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2001